ArticleNeurodegenerative disease management2025
Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease.
Article in Neurodegenerative disease management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we aimed to investigate the clinical features of a large group of patients with Parkinson's disease (PD), paying particular attention to the nonmotor symptom (NMS) load. Secondly, we aimed to investigate the clinical correlates of NMSs using the results of various clinical assessments.
methodsData from all PD patients who visited our movement disorders clinic between January 2023 and March 2024 were retrospectively reviewed. We included the data of all patients whose information regarding clinical features and extensive scale results were available.
resultsOverall, we included data from 285 PD patients with a mean age of 64.5 ± 10.0 years (F/M = 119/166). The median scores of the MDS-UPDRS subparts were 9 for MDS-UPDRS-1 and 30 for MDS-UPDRS-3 (off). The median NMSS score was 38 (range: 229), and 46% of the patients had severe to very severe disease in terms of NMS burden. The regression analyses revealed the MDS-UPDRS 3 score, FES-I score, and RBD (0.9772 + 0.453*MDS-UPDRS 3 + 0.724 * FES-I + 15.192*RBD) as predictors of the NMS scale.
conclusionsWe found a very high NMS burden in our PD cohort. Remarkably, RBD, motor stage, and concern about falling were found to correlate with NMS load.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.